JP2001523731A - 増殖している細胞を治療するための増殖活性生成物 - Google Patents

増殖している細胞を治療するための増殖活性生成物

Info

Publication number: JP2001523731A
Authority: JP; Japan
Prior art keywords: product; biologically active; cells; product according; cytokine
Prior art date: 1997-11-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2000521861A

Other languages

English (en)

Japanese (ja)

Inventor

フランクス，クリストファー・ラルフ

デラ・ビッタ，ルッジェロ

Original Assignee

バイオイノヴェイション・リミテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-11-26

Filing date

1998-11-25

Publication date

2001-11-27

1998-11-25 Application filed by バイオイノヴェイション・リミテッド filed Critical バイオイノヴェイション・リミテッド

2001-11-27 Publication of JP2001523731A publication Critical patent/JP2001523731A/ja

Status Pending legal-status Critical Current

Links

108010002350 Interleukin-2 Proteins 0.000 claims abstract description 106
102000004127 Cytokines Human genes 0.000 claims abstract description 77
108090000695 Cytokines Proteins 0.000 claims abstract description 77
239000003102 growth factor Substances 0.000 claims abstract description 63
239000013543 active substance Substances 0.000 claims abstract description 62
108090000623 proteins and genes Proteins 0.000 claims abstract description 49
150000001875 compounds Chemical class 0.000 claims abstract description 43
230000002062 proliferating effect Effects 0.000 claims abstract description 34
239000004480 active ingredient Substances 0.000 claims abstract description 27
239000002773 nucleotide Substances 0.000 claims abstract description 25
125000003729 nucleotide group Chemical group 0.000 claims abstract description 25
239000003814 drug Substances 0.000 claims abstract description 23
230000000692 anti-sense effect Effects 0.000 claims abstract description 21
239000003795 chemical substances by application Substances 0.000 claims abstract description 16
230000012010 growth Effects 0.000 claims abstract description 14
230000015572 biosynthetic process Effects 0.000 claims abstract description 9
238000003786 synthesis reaction Methods 0.000 claims abstract description 9
238000004519 manufacturing process Methods 0.000 claims abstract description 7
230000001028 anti-proliverative effect Effects 0.000 claims abstract description 6
102000000588 Interleukin-2 Human genes 0.000 claims description 105
210000004027 cell Anatomy 0.000 claims description 96
102000005962 receptors Human genes 0.000 claims description 92
108020003175 receptors Proteins 0.000 claims description 92
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 41
210000004698 lymphocyte Anatomy 0.000 claims description 41
201000010099 disease Diseases 0.000 claims description 35
238000000034 method Methods 0.000 claims description 29
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 26
108010036949 Cyclosporine Proteins 0.000 claims description 26
229960001265 ciclosporin Drugs 0.000 claims description 26
229930182912 cyclosporin Natural products 0.000 claims description 22
208000023275 Autoimmune disease Diseases 0.000 claims description 16
229930105110 Cyclosporin A Natural products 0.000 claims description 14
239000003018 immunosuppressive agent Substances 0.000 claims description 14
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 13
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 13
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 13
229960000485 methotrexate Drugs 0.000 claims description 13
102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 12
108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 12
230000006870 function Effects 0.000 claims description 12
229960003444 immunosuppressant agent Drugs 0.000 claims description 12
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 9
102000004889 Interleukin-6 Human genes 0.000 claims description 9
108090001005 Interleukin-6 Proteins 0.000 claims description 9
102000013275 Somatomedins Human genes 0.000 claims description 9
229960002170 azathioprine Drugs 0.000 claims description 9
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 9
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 8
229940122803 Vinca alkaloid Drugs 0.000 claims description 8
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 8
150000001413 amino acids Chemical class 0.000 claims description 8
230000035755 proliferation Effects 0.000 claims description 8
230000003612 virological effect Effects 0.000 claims description 8
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 7
206010052779 Transplant rejections Diseases 0.000 claims description 7
-1 platinum coordination complex Chemical class 0.000 claims description 7
229960003433 thalidomide Drugs 0.000 claims description 7
102000003951 Erythropoietin Human genes 0.000 claims description 6
108090000394 Erythropoietin Proteins 0.000 claims description 6
108010009583 Transforming Growth Factors Proteins 0.000 claims description 6
239000002246 antineoplastic agent Substances 0.000 claims description 6
208000035475 disorder Diseases 0.000 claims description 6
229940105423 erythropoietin Drugs 0.000 claims description 6
230000001861 immunosuppressant effect Effects 0.000 claims description 6
239000000813 peptide hormone Substances 0.000 claims description 6
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical group [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 6
108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 5
102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 5
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 5
150000003212 purines Chemical class 0.000 claims description 5
210000000130 stem cell Anatomy 0.000 claims description 5
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 4
108010006654 Bleomycin Proteins 0.000 claims description 4
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
108010092160 Dactinomycin Proteins 0.000 claims description 4
102000000646 Interleukin-3 Human genes 0.000 claims description 4
108010002386 Interleukin-3 Proteins 0.000 claims description 4
108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 4
102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 4
102000011117 Transforming Growth Factor beta2 Human genes 0.000 claims description 4
101800000304 Transforming growth factor beta-2 Proteins 0.000 claims description 4
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 4
229960001561 bleomycin Drugs 0.000 claims description 4
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 4
239000003246 corticosteroid Substances 0.000 claims description 4
229960004397 cyclophosphamide Drugs 0.000 claims description 4
229960000640 dactinomycin Drugs 0.000 claims description 4
239000003166 dihydrofolate reductase inhibitor Substances 0.000 claims description 4
229910052697 platinum Inorganic materials 0.000 claims description 4
150000003230 pyrimidines Chemical class 0.000 claims description 4
229910052702 rhenium Inorganic materials 0.000 claims description 4
WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims description 4
229940072041 transforming growth factor beta 2 Drugs 0.000 claims description 4
229910052727 yttrium Inorganic materials 0.000 claims description 4
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims description 4
229940117937 Dihydrofolate reductase inhibitor Drugs 0.000 claims description 3
102100039897 Interleukin-5 Human genes 0.000 claims description 3
108010002616 Interleukin-5 Proteins 0.000 claims description 3
239000002532 enzyme inhibitor Substances 0.000 claims description 3
229940125532 enzyme inhibitor Drugs 0.000 claims description 3
239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 3
208000030289 Lymphoproliferative disease Diseases 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
229940076264 interleukin-3 Drugs 0.000 claims description 2
229940100602 interleukin-5 Drugs 0.000 claims description 2
230000004936 stimulating effect Effects 0.000 claims description 2
102100040247 Tumor necrosis factor Human genes 0.000 claims 3
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
239000008194 pharmaceutical composition Substances 0.000 claims 2
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
102100040019 Interferon alpha-1/13 Human genes 0.000 claims 1
238000005903 acid hydrolysis reaction Methods 0.000 claims 1
239000002260 anti-inflammatory agent Substances 0.000 claims 1
229940121363 anti-inflammatory agent Drugs 0.000 claims 1
229940088623 biologically active substance Drugs 0.000 claims 1
201000001268 lymphoproliferative syndrome Diseases 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
230000001177 retroviral effect Effects 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 28
108091028043 Nucleic acid sequence Proteins 0.000 abstract description 3
239000000047 product Substances 0.000 description 80
210000001744 T-lymphocyte Anatomy 0.000 description 30
102000004169 proteins and genes Human genes 0.000 description 24
235000018102 proteins Nutrition 0.000 description 23
230000001506 immunosuppresive effect Effects 0.000 description 18
230000004927 fusion Effects 0.000 description 17
229940079593 drug Drugs 0.000 description 14
230000027455 binding Effects 0.000 description 13
241000725303 Human immunodeficiency virus Species 0.000 description 12
206010028980 Neoplasm Diseases 0.000 description 12
238000002512 chemotherapy Methods 0.000 description 12
238000001727 in vivo Methods 0.000 description 12
238000011282 treatment Methods 0.000 description 12
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 11
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 11
206010062016 Immunosuppression Diseases 0.000 description 11
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 11
239000000427 antigen Substances 0.000 description 11
108091007433 antigens Proteins 0.000 description 11
102000036639 antigens Human genes 0.000 description 11
210000000056 organ Anatomy 0.000 description 11
108020004414 DNA Proteins 0.000 description 10
239000002738 chelating agent Substances 0.000 description 10
230000003834 intracellular effect Effects 0.000 description 10
210000002540 macrophage Anatomy 0.000 description 10
102000004196 processed proteins & peptides Human genes 0.000 description 10
108090000765 processed proteins & peptides Proteins 0.000 description 10
230000001988 toxicity Effects 0.000 description 10
231100000419 toxicity Toxicity 0.000 description 10
230000007812 deficiency Effects 0.000 description 9
229920001184 polypeptide Polymers 0.000 description 9
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 9
230000001154 acute effect Effects 0.000 description 8
210000002950 fibroblast Anatomy 0.000 description 8
210000000987 immune system Anatomy 0.000 description 8
229940100601 interleukin-6 Drugs 0.000 description 8
230000000144 pharmacologic effect Effects 0.000 description 8
239000012925 reference material Substances 0.000 description 8
230000010076 replication Effects 0.000 description 8
230000009885 systemic effect Effects 0.000 description 8
239000013598 vector Substances 0.000 description 8
239000004971 Cross linker Substances 0.000 description 7
102000018233 Fibroblast Growth Factor Human genes 0.000 description 7
108050007372 Fibroblast Growth Factor Proteins 0.000 description 7
102000015696 Interleukins Human genes 0.000 description 7
108010063738 Interleukins Proteins 0.000 description 7
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
229940126864 fibroblast growth factor Drugs 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
229960002555 zidovudine Drugs 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
108010050904 Interferons Proteins 0.000 description 6
102000014150 Interferons Human genes 0.000 description 6
230000001363 autoimmune Effects 0.000 description 6
230000000903 blocking effect Effects 0.000 description 6
210000001185 bone marrow Anatomy 0.000 description 6
230000014509 gene expression Effects 0.000 description 6
230000003394 haemopoietic effect Effects 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
229940079322 interferon Drugs 0.000 description 6
230000001575 pathological effect Effects 0.000 description 6
208000011580 syndromic disease Diseases 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
230000009471 action Effects 0.000 description 5
230000004913 activation Effects 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 5
230000000798 anti-retroviral effect Effects 0.000 description 5
210000003719 b-lymphocyte Anatomy 0.000 description 5
230000008901 benefit Effects 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
231100000433 cytotoxic Toxicity 0.000 description 5
231100000599 cytotoxic agent Toxicity 0.000 description 5
230000001472 cytotoxic effect Effects 0.000 description 5
239000002619 cytotoxin Substances 0.000 description 5
238000009826 distribution Methods 0.000 description 5
210000001163 endosome Anatomy 0.000 description 5
230000005713 exacerbation Effects 0.000 description 5
108020001507 fusion proteins Proteins 0.000 description 5
102000037865 fusion proteins Human genes 0.000 description 5
208000024908 graft versus host disease Diseases 0.000 description 5
210000002865 immune cell Anatomy 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
208000032839 leukemia Diseases 0.000 description 5
239000000203 mixture Substances 0.000 description 5
229940002612 prodrug Drugs 0.000 description 5
239000000651 prodrug Substances 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
210000003491 skin Anatomy 0.000 description 5
210000001835 viscera Anatomy 0.000 description 5
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
102000007644 Colony-Stimulating Factors Human genes 0.000 description 4
108010071942 Colony-Stimulating Factors Proteins 0.000 description 4
102000003886 Glycoproteins Human genes 0.000 description 4
108090000288 Glycoproteins Proteins 0.000 description 4
208000031886 HIV Infections Diseases 0.000 description 4
208000037357 HIV infectious disease Diseases 0.000 description 4
108010029485 Protein Isoforms Proteins 0.000 description 4
102000001708 Protein Isoforms Human genes 0.000 description 4
206010039710 Scleroderma Diseases 0.000 description 4
102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
230000000259 anti-tumor effect Effects 0.000 description 4
229940088710 antibiotic agent Drugs 0.000 description 4
230000001588 bifunctional effect Effects 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
102000003675 cytokine receptors Human genes 0.000 description 4
108010057085 cytokine receptors Proteins 0.000 description 4
210000000805 cytoplasm Anatomy 0.000 description 4
230000005714 functional activity Effects 0.000 description 4
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 4
230000008004 immune attack Effects 0.000 description 4
230000003993 interaction Effects 0.000 description 4
230000036210 malignancy Effects 0.000 description 4
210000002997 osteoclast Anatomy 0.000 description 4
230000008569 process Effects 0.000 description 4
230000000284 resting effect Effects 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
231100000057 systemic toxicity Toxicity 0.000 description 4
230000000451 tissue damage Effects 0.000 description 4
231100000827 tissue damage Toxicity 0.000 description 4
QLHLYJHNOCILIT-UHFFFAOYSA-N 4-o-(2,5-dioxopyrrolidin-1-yl) 1-o-[2-[4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoyl]oxyethyl] butanedioate Chemical compound O=C1CCC(=O)N1OC(=O)CCC(=O)OCCOC(=O)CCC(=O)ON1C(=O)CCC1=O QLHLYJHNOCILIT-UHFFFAOYSA-N 0.000 description 3
208000030507 AIDS Diseases 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 3
101710112752 Cytotoxin Proteins 0.000 description 3
108010053187 Diphtheria Toxin Proteins 0.000 description 3
102000016607 Diphtheria Toxin Human genes 0.000 description 3
208000036566 Erythroleukaemia Diseases 0.000 description 3
208000030836 Hashimoto thyroiditis Diseases 0.000 description 3
102100034349 Integrase Human genes 0.000 description 3
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 3
102000009618 Transforming Growth Factors Human genes 0.000 description 3
241000700605 Viruses Species 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
208000005980 beta thalassemia Diseases 0.000 description 3
208000022806 beta-thalassemia major Diseases 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
210000004970 cd4 cell Anatomy 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
231100000313 clinical toxicology Toxicity 0.000 description 3
229940047120 colony stimulating factors Drugs 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
238000012937 correction Methods 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
150000002148 esters Chemical group 0.000 description 3
239000012634 fragment Substances 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
230000003308 immunostimulating effect Effects 0.000 description 3
229940124589 immunosuppressive drug Drugs 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000003446 ligand Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
210000002751 lymph Anatomy 0.000 description 3
210000001165 lymph node Anatomy 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
229960001428 mercaptopurine Drugs 0.000 description 3
230000008506 pathogenesis Effects 0.000 description 3
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000000717 retained effect Effects 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
208000007056 sickle cell anemia Diseases 0.000 description 3
230000008685 targeting Effects 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
108020004491 Antisense DNA Proteins 0.000 description 2
108020005544 Antisense RNA Proteins 0.000 description 2
208000020084 Bone disease Diseases 0.000 description 2
206010051779 Bone marrow toxicity Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
208000009329 Graft vs Host Disease Diseases 0.000 description 2
206010018691 Granuloma Diseases 0.000 description 2
102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
208000003695 Histiocytic Necrotizing Lymphadenitis Diseases 0.000 description 2
206010069070 Histiocytic necrotising lymphadenitis Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
102000001617 Interferon Receptors Human genes 0.000 description 2
108010054267 Interferon Receptors Proteins 0.000 description 2
108010047761 Interferon-alpha Proteins 0.000 description 2
102000006992 Interferon-alpha Human genes 0.000 description 2
208000015282 Kikuchi-Fujimoto disease Diseases 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
208000015439 Lysosomal storage disease Diseases 0.000 description 2
108010021466 Mutant Proteins Proteins 0.000 description 2
102000008300 Mutant Proteins Human genes 0.000 description 2
201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 2
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
102000003992 Peroxidases Human genes 0.000 description 2
108010083204 Proton Pumps Proteins 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
206010047115 Vasculitis Diseases 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
208000021841 acute erythroid leukemia Diseases 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
229940124522 antiretrovirals Drugs 0.000 description 2
239000003903 antiretrovirus agent Substances 0.000 description 2
239000003816 antisense DNA Substances 0.000 description 2
230000003140 astrocytic effect Effects 0.000 description 2
239000007998 bicine buffer Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000001772 blood platelet Anatomy 0.000 description 2
231100000366 bone marrow toxicity Toxicity 0.000 description 2
238000010322 bone marrow transplantation Methods 0.000 description 2
230000020411 cell activation Effects 0.000 description 2
230000003915 cell function Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
239000003184 complementary RNA Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
238000012258 culturing Methods 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
230000000925 erythroid effect Effects 0.000 description 2
210000003013 erythroid precursor cell Anatomy 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000010363 gene targeting Methods 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
210000004565 granule cell Anatomy 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000037451 immune surveillance Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000011630 iodine Substances 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000007774 longterm Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
150000002894 organic compounds Chemical class 0.000 description 2
210000000963 osteoblast Anatomy 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
230000003076 paracrine Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000037361 pathway Effects 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
201000000306 sarcoidosis Diseases 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000007863 steatosis Effects 0.000 description 2
231100000240 steatosis hepatitis Toxicity 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000014616 translation Effects 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
XQUPVDVFXZDTLT-UHFFFAOYSA-N 1-[4-[[4-(2,5-dioxopyrrol-1-yl)phenyl]methyl]phenyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C(C=C1)=CC=C1CC1=CC=C(N2C(C=CC2=O)=O)C=C1 XQUPVDVFXZDTLT-UHFFFAOYSA-N 0.000 description 1
RWSYPPRKMNWNII-JECWBDJGSA-N 19a86zw520 Chemical compound C([C@@]12[C@@H](C)[C@@H]([C@@H]3[C@H]([C@H]([C@H](C)[C@H]4O[C@H]5C[C@@H](C)C[C@H]6O[C@@]7(C)[C@H](O)C[C@H]8O[C@H]9C=C[C@H]%10O[C@H]%11C[C@@H]%12[C@H]([C@@H]([C@H]%13O[C@H](C=CC[C@@H]%13O%12)\C=C\[C@H](O)CO)O)O[C@@H]%11C=C[C@@H]%10O[C@@H]9C\C=C/C[C@@H]8O[C@@H]7C[C@@H]6O[C@@H]5C[C@@H]4O3)O)O2)C)CCO1 RWSYPPRKMNWNII-JECWBDJGSA-N 0.000 description 1
208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
201000000736 Amenorrhea Diseases 0.000 description 1
206010001928 Amenorrhoea Diseases 0.000 description 1
206010003594 Ataxia telangiectasia Diseases 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
206010003827 Autoimmune hepatitis Diseases 0.000 description 1
206010055128 Autoimmune neutropenia Diseases 0.000 description 1
208000027496 Behcet disease Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
208000005243 Chondrosarcoma Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
208000027205 Congenital disease Diseases 0.000 description 1
206010054002 Congenital syphilitic osteochondritis Diseases 0.000 description 1
208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 1
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
206010012434 Dermatitis allergic Diseases 0.000 description 1
208000000398 DiGeorge Syndrome Diseases 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
208000004232 Enteritis Diseases 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
241001646716 Escherichia coli K-12 Species 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
208000001948 Farber Lipogranulomatosis Diseases 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
208000015872 Gaucher disease Diseases 0.000 description 1
208000020322 Gaucher disease type I Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
102000004547 Glucosylceramidase Human genes 0.000 description 1
108010017544 Glucosylceramidase Proteins 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
208000001204 Hashimoto Disease Diseases 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 1
101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
208000028782 Hereditary disease Diseases 0.000 description 1
101100232904 Homo sapiens IL2 gene Proteins 0.000 description 1
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
208000019758 Hypergammaglobulinemia Diseases 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
102100026720 Interferon beta Human genes 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
LPGWZGMPDKDHEP-GKWAKPNHSA-N Leurosine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@]6(CC)O[C@@H]6[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C LPGWZGMPDKDHEP-GKWAKPNHSA-N 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 description 1
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
206010064912 Malignant transformation Diseases 0.000 description 1
208000024556 Mendelian disease Diseases 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
206010028116 Mucosal inflammation Diseases 0.000 description 1
201000010927 Mucositis Diseases 0.000 description 1
208000034486 Multi-organ failure Diseases 0.000 description 1
208000010718 Multiple Organ Failure Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
101000761736 Naja atra Cytotoxin 10 Proteins 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010061309 Neoplasm progression Diseases 0.000 description 1
206010029155 Nephropathy toxic Diseases 0.000 description 1
102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
108010011356 Nucleoside phosphotransferase Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
108010089814 Plant Lectins Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
208000008601 Polycythemia Diseases 0.000 description 1
102100032709 Potassium-transporting ATPase alpha chain 2 Human genes 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
102000006270 Proton Pumps Human genes 0.000 description 1
206010061924 Pulmonary toxicity Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
208000007660 Residual Neoplasm Diseases 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
230000010782 T cell mediated cytotoxicity Effects 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
238000007792 addition Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
208000037844 advanced solid tumor Diseases 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
231100000540 amenorrhea Toxicity 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003527 anti-angiogenesis Effects 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
230000002634 anti-blastic effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
230000007503 antigenic stimulation Effects 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000003972 antineoplastic antibiotic Substances 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
230000006470 autoimmune attack Effects 0.000 description 1
201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
230000006472 autoimmune response Effects 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
206010003883 azoospermia Diseases 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
ZSNFGVQUPMRCIP-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) butanedioate Chemical compound O=C1CCC(=O)N1OC(=O)CCC(=O)ON1C(=O)CCC1=O ZSNFGVQUPMRCIP-UHFFFAOYSA-N 0.000 description 1
210000003969 blast cell Anatomy 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
201000008274 breast adenocarcinoma Diseases 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
239000013522 chelant Substances 0.000 description 1
CRQQGFGUEAVUIL-UHFFFAOYSA-N chlorothalonil Chemical compound ClC1=C(Cl)C(C#N)=C(Cl)C(C#N)=C1Cl CRQQGFGUEAVUIL-UHFFFAOYSA-N 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000024203 complement activation Effects 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
239000000039 congener Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
230000001909 effect on DNA Effects 0.000 description 1
210000003162 effector t lymphocyte Anatomy 0.000 description 1
210000003372 endocrine gland Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
210000001339 epidermal cell Anatomy 0.000 description 1
210000002514 epidermal stem cell Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
210000000267 erythroid cell Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
201000008049 fucosidosis Diseases 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
239000003168 generic drug Substances 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
208000009817 glycoprotein storage disease Diseases 0.000 description 1
239000007952 growth promoter Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
201000008298 histiocytosis Diseases 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
230000037417 hyperactivation Effects 0.000 description 1
230000000642 iatrogenic effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
238000002650 immunosuppressive therapy Methods 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
208000021267 infertility disease Diseases 0.000 description 1
201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
108010078376 interleukin 2-diphtheria toxin Proteins 0.000 description 1
230000004073 interleukin-2 production Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000008316 intracellular mechanism Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
231100001022 leukopenia Toxicity 0.000 description 1
230000013190 lipid storage Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
230000000998 lymphohematopoietic effect Effects 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
230000003526 lymphopoietic effect Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000036212 malign transformation Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
244000005700 microbiome Species 0.000 description 1
210000000274 microglia Anatomy 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
210000000066 myeloid cell Anatomy 0.000 description 1
208000025113 myeloid leukemia Diseases 0.000 description 1
230000008693 nausea Effects 0.000 description 1
MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
230000010309 neoplastic transformation Effects 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
230000007694 nephrotoxicity Effects 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000009206 nuclear medicine Methods 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
239000012038 nucleophile Substances 0.000 description 1
125000002524 organometallic group Chemical group 0.000 description 1
150000002905 orthoesters Chemical class 0.000 description 1
210000004409 osteocyte Anatomy 0.000 description 1
230000000010 osteolytic effect Effects 0.000 description 1
229940127084 other anti-cancer agent Drugs 0.000 description 1
229960003552 other antineoplastic agent in atc Drugs 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
229960003330 pentetic acid Drugs 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
230000007180 physiological regulation Effects 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
239000003726 plant lectin Substances 0.000 description 1
210000001778 pluripotent stem cell Anatomy 0.000 description 1
231100000374 pneumotoxicity Toxicity 0.000 description 1
229920003192 poly(bis maleimide) Polymers 0.000 description 1
230000003234 polygenic effect Effects 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
239000002243 precursor Substances 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
230000035752 proliferative phase Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000007047 pulmonary toxicity Effects 0.000 description 1
239000002212 purine nucleoside Substances 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000011363 radioimmunotherapy Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
238000000926 separation method Methods 0.000 description 1
208000002491 severe combined immunodeficiency Diseases 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000010009 steroidogenesis Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
210000002978 thoracic duct Anatomy 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
229960004355 vindesine Drugs 0.000 description 1
UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
229950009832 vinleurosine Drugs 0.000 description 1
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
229960002066 vinorelbine Drugs 0.000 description 1
230000009278 visceral effect Effects 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

JP2000521861A 1997-11-26 1998-11-25 増殖している細胞を治療するための増殖活性生成物 Pending JP2001523731A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9724838.9		1997-11-26
GBGB9724838.9A GB9724838D0 (en)	1997-11-26	1997-11-26	Compositions
PCT/GB1998/003509 WO1999026660A2 (fr)	1997-11-26	1998-11-25	Produit a activite proliferative utile pour traiter des cellules proliferatives

Publications (1)

Publication Number	Publication Date
JP2001523731A true JP2001523731A (ja)	2001-11-27

Family

ID=10822573

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2000521861A Pending JP2001523731A (ja)	1997-11-26	1998-11-25	増殖している細胞を治療するための増殖活性生成物

Country Status (8)

Country	Link
EP (1)	EP1032427A2 (fr)
JP (1)	JP2001523731A (fr)
AU (1)	AU1249999A (fr)
CA (1)	CA2311733A1 (fr)
GB (1)	GB9724838D0 (fr)
NZ (1)	NZ504625A (fr)
WO (1)	WO1999026660A2 (fr)
ZA (1)	ZA9810759B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003501402A (ja) *	1999-06-03	2003-01-14	バイオイノベイション・リミテッド	遺伝子治療用生成物
US7868011B2 (en)	2003-04-09	2011-01-11	General Atomics	Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
US7196093B2 (en)	2003-04-09	2007-03-27	General Atomics	Reversible inhibitors of SAH hydrolase and uses thereof
US7517887B2 (en) *	2003-04-09	2009-04-14	General Atomics	Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
BR112013023151A2 (pt)	2011-03-11	2020-09-15	Assistance Publique - Hôpitaux De Paris	interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado
DK2683395T3 (en)	2011-03-11	2018-11-19	Hopitaux Paris Assist Publique	USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3873887T2 (de) *	1987-12-02	1993-02-04	Neorx Corp	Spaltbare immun-conjugate fuer die abgabe und freisetzung von agenzien in natuerlicher form.
CA2016584C (fr) *	1989-05-17	1999-06-29	Robert S. Greenfield	Conjugats d'anthracycline ayant un nouvel adapteur et methodes de production
JP3105629B2 (ja) *	1991-04-23	2000-11-06	サングスタットメディカルコーポレイション	特異的結合ペアのメンバーの細胞活性調節接合体
US5248499A (en) *	1991-10-07	1993-09-28	Genentech, Inc.	Control of microbial infections in transplant patients
US6214345B1 (en) *	1993-05-14	2001-04-10	Bristol-Myers Squibb Co.	Lysosomal enzyme-cleavable antitumor drug conjugates
US5635599A (en) *	1994-04-08	1997-06-03	The United States Of America As Represented By The Department Of Health And Human Services	Fusion proteins comprising circularly permuted ligands

1997
- 1997-11-26 GB GBGB9724838.9A patent/GB9724838D0/en not_active Ceased
1998
- 1998-11-25 WO PCT/GB1998/003509 patent/WO1999026660A2/fr not_active Ceased
- 1998-11-25 AU AU12499/99A patent/AU1249999A/en not_active Abandoned
- 1998-11-25 ZA ZA9810759A patent/ZA9810759B/xx unknown
- 1998-11-25 JP JP2000521861A patent/JP2001523731A/ja active Pending
- 1998-11-25 CA CA002311733A patent/CA2311733A1/fr not_active Abandoned
- 1998-11-25 EP EP98955771A patent/EP1032427A2/fr not_active Withdrawn
- 1998-11-25 NZ NZ504625A patent/NZ504625A/xx unknown

Also Published As

Publication number	Publication date
ZA9810759B (en)	2000-05-25
GB9724838D0 (en)	1998-01-21
CA2311733A1 (fr)	1999-06-03
AU1249999A (en)	1999-06-15
WO1999026660A3 (fr)	1999-10-14
WO1999026660A2 (fr)	1999-06-03
NZ504625A (en)	2002-12-20
EP1032427A2 (fr)	2000-09-06

Publication	Publication Date	Title
US7371371B2 (en)	2008-05-13	Interleukin-2 mutants with reduced toxicity
Revoltella et al.	2012	Granulocyte–macrophage colony-stimulating factor as an autocrine survival-growth factor in human gliomas
US6248319B1 (en)	2001-06-19	Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides
US7144731B2 (en)	2006-12-05	SCF antibody compositions and methods of using the same
KR20010102043A (ko)	2001-11-15	항-혈관형성 요법 및 면역요법을 병용한 종양 및 전이의치료 방법
EP0354729A2 (fr)	1990-02-14	Conjugués de médicaments cytotoxiques
PT95524B (pt)	1997-08-29	Novos factores poliptidicos com actividade estimuladora de celulas indiferenciadas, processo para a sua preparacao e para a preparacao de composicoes farmaceuticas que os contem
EP0704221A2 (fr)	1996-04-03	Conjugué applicable dans le transfert de gènes et sa méthode de préparation
WO2021018026A1 (fr)	2021-02-04	Préparation liquide et son application
CN113597304A (zh)	2021-11-02	原发性中枢神经系统淋巴瘤的组合治疗
JP2001523731A (ja)	2001-11-27	増殖している細胞を治療するための増殖活性生成物
CA2056555A1 (fr)	1992-05-30	Agent immunostimulant renfermant de l'interleucine-2 et de la 5'-desoxy-5-fluoro-uridine
US6207454B1 (en)	2001-03-27	Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
JPWO1996010089A1 (ja)	1997-07-29	ペプチド及び蛋白質の修飾
Garnick et al.	1989	Clinical promise of new hematopoietic growth factors: M-CSF, IL-3, IL-6
WO2000074724A2 (fr)	2000-12-14	Produits de therapie genique
AU2019370284B2 (en)	2025-01-30	Combination therapy method of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate in combination with other agents
Thomas et al.	1989	Biological approaches to cancer therapy
CA2198919A1 (fr)	1996-03-07	Modification graduelle, super-agonistes et antagonistes de peptides et de proteines-signaux
Boyano et al.	1999	Cyclosporin A Upmodulates the α-Subunit of the Interleukin-2 Receptor and the Metastatic Ability of Murine B16F10 Melanoma Cells
WO1993005801A1 (fr)	1993-04-01	Utilisation de l'il-5 pour traiter des tumeurs solides
AU2003248017A1 (en)	2003-10-30	Gradual modification super-agonists and antagonists of signal-proteins and peptides
AU2007200889A1 (en)	2007-03-29	Gradual modification super-agonists and antagonists of signal-proteins and peptides